Skip to main content

Table 1 Characteristics of 61 patients undergoing SRT and comparison of SRT success group and SRT failure group

From: Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study

Variables Total (n = 61) SRT success (n = 30) SRT failure (n = 31 ) SRT Success vs SRT failure P value
Age at SRT (median, range) 69 (57–78) 70 (58–77) 69 (57–78) 0.88 †
Initial PSA (mean, SD) 12.5 ± 14.5 14.3 ± 19.7 10.7 ± 6.4 0.96 †
Clinical T stage     0.47 ‡
T1c 24 13 11  
T2 29 12 17  
T3 8 5 3  
NCCN risk classification     0.086 ‡
Low 10 8 2  
Intermidiate 28 11 17  
High / Very high 23 11 12  
Prostatectomy Gleason score     0.17 ‡
6 6 5 1  
7 35 18 17  
8 8 2 6  
9 12 5 7  
Prostatectomy pathological T stage     0.84 ‡
T2a 10 6 4  
T2b 10 4 6  
T2c 14 7 7  
T3a / b 27 13 14  
Prostatectomy lymphatic invasion (ly)     0.23 ‡
Negative 46 25 21  
Positive 15 5 10  
Prostatectomy perineural invasion (pn)     0.79 ‡
Negative 23 12 11  
Positive 38 18 20  
Prostatectomy Seminal vesicle involvement     0.97 ‡
Negative 57 28 29  
Positive 4 2 2  
Surgical margins     0.075 ‡
Negative 30 11 19  
Positive 31 19 12  
Time to PSA nadir after prostatectomy (months) 2.4 (0.8 - 17.9) 2.3 (0.8 - 15.8) 2.5 (0.9 - 17.9) 0.22 †
PSA nadir after prostatectomy (ng/mL) 0.140 ± 0.238 0.116 ± 0.214 0.163 ± 0.262 0.35 †
Pre-SRT PSA (ng/mL) 0.56 ± 0.49 0.37 ± 0.25 0.75 ± 0.59 0.021 †
PSAV after PSA recurrence (ng/mL/year) 0.19 ± 1.40 0.38 ± 0.40 1.43 ± 1.79 < 0.0001 †
PSADT after PSA recurrence (months) 7.44 ± 7.27 9.89 ± 9.02 5.07 ± 3.94 0.0049 †
Follow up period after SRT (months) 29.6 (12.0 - 70.0) 24.6 (12.0 - 70.0) 31.2 (12.0 - 64.6) 0.83 †
  1. SRT = salvage radiotherapy; PSA = prostate-specific antigen; SD = standard deviation; NCCN = The National Comprehensive Cancer Network; PSAV = PSA velocity; PSADT = PSA doubling time; † Man-Whitney U test; ‡ Chi-square test or Fisher’s exact test.